Telmisartan versus EnalapRil In heart failure with redUced ejection fraction patients with Moderately impaired kidney Functions; randomized controlled trial: “TRIUMF trial”

The Egyptian Heart Journal

Table 2 Data of baseline-to-3-months period

	Telmisartan	Enalapril	P-value
RAASi standardized dose*	100% [100–100]	50% [25–100]	< 0.001
Achieving ≥ 50% of the target RAASi dose	93.5%	68.6%	0.002
Occurrence of DR	10.6%	32.7%	0.008
Composite of DR-DC	31.9%	55.1%	0.018
Peak serum creatinine	1.68 ± 0.57	1.63 ± 0.50	0.61
Estimated GFR	48.89 ± 12.44	54.04 ± 17.86	0.11
Serum potassium	4.64 ± 0.56	4.57 ± 0.71	0.72
Rate of WRF (1)	14%	20.8%	0.31
Rate of WRF (2)	8.5%	12.5%	0.384
Rate of WRF (3)	6.4%	22.9%	0.022
Maintaining MRA therapy	89.4%	87.5%	0.51
Maintaining BB therapy	87.2%	93.8%	0.23
BB standardized dose*	39.4 ± 33.5%	43.2 ± 32.4%	0.569
Loop diuretic standardized dose^†	109 ± 126	125 ± 113	0.362
Composite of all-cause death and/or HHF	22.4%	28%	0.343
All-cause death	4%	4%	0.684
HFH	18.4%	28%	0.185
NYHA classification at 3-months [n (%)]
I–II	30 (63.8%)	33 (68.8%)	0.785
III	11 (23.4%)	8 (16.7%)
IV	6 (12.8%)	7 (14.6%)
NYHA class shifts between baseline-to-3-months	0 [− 1, 0]	0 [− 1, 0]	0.616

Bold refers to statistically significant p value
BB—Beta adrenergic blocker; DC—discontinuation; DR—dose reduction; GFR—glomerular filtration rate; HFH—heart failure re-hospitalization; MRA—Mineralocorticoid antagonists; NYHA—New York Heart Association class; RAASi—Renin–angiotensin–aldosterone system inhibitors; WRF—worsening renal function defined as absolute rise in the serum creatinine by 0.3 mg/dl, or by 0.5 mg/dl or as relative decline of the eGFR by ≥ 20% compared to prior assessments in (1), (2) and (3), respectively
^*Representing percentage from the target dose
^†Expressed in mean ± standard deviation (SD) of Frusemide equivalents, considering 20 mg of Torsemide, 1 mg of Bumetanide and 40 mg of Frusemide as equivalents